		REPORT OF VERIFIED CASE
(First)	(M.I.)	OF TUBERCULOSIS

	(Last)	(First)	(IVI.I.)
Street Address			

OF TUBERCULO (ZIP CODE)



Patient's Name _

REPORT OF VERIFIED CASE OF TUBERCULOSIS

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES-FORM APPROVED OMB NO. 0920-0026 Exp. Date 05/31/2011

1. Date Reported	3. Case Numbers Year Reported (vvv.	Assigned Identification Number
INV111	State Case Number	INV173	Assigned Refulledation Humber
	City/County Case Number	INV172	
2. Date Submitted			Reason:
Month	Linking State Case Number	TB207	TB208
INV177	Linking State Case Number	TB209	TD040
			TB210
4. Reporting Address for Case Counting		8. Date of Birth	
City TB08		LI DE	M115 Year
Within City Limits (select one)	TB099	9. Sex at Birth (se	elect one) 11. Race (select one or more)
County TB08		DEM1	14 DEM152
ZIP CODE TB08	2	10. Ethnicity (selec	ot one) Asian. Specny Black or African American
5. Count Status (select one) 6	. Date Counted	DEM1	Notive Deliver
Countable TB Case	TB100	ear Or Latino	Specify
Count as a TB case		10 Otr. of Birth	White
TB153 ted by	Previous Diagnosis of TB Disease	"U.Sborn" (or I	born abroa DEM2003 en)
another U.S. area (e.g., county, state)	□Yes □Nc <mark>TB10</mark>	(select one) Country of birth	
Verified Casinitiated in a TB211	If YES, enter year of previous TB dise	- I	rived in U.S.
Verified Case: Recurrent TB within 12	TB103	Month	Year
months after completion of therapy	10103	DEIN	2005
14. Pediatric TB Patients (<15 years old)	TD047	16. Site of TB Disease (select all th	at apply)
Country of Birth for Primary Guardian(s): Specif			_
Guardian 1 Guardian 2	TB218		Taenitourinary
Patient lived outside U.S. for >2 months? (select one)	TB215 Unknown		Meningeal
If YES, list countries, specify:	TB216	` `	Peritoneal
15. Status at TB Diagnosis (select one)	15210		Other: Enter anatomic code(s) (see list):
□ Alive □ Dea TB101	Day Year	☐ Lymphatic: Other ☐ Lymphatic: Unknown	Site not stated
If DEAD, enter date of death:	IV146	Laryngeal	3
If DEAD, was TB a cause of death? (sele	B220		

Public reporting burden of this collection of information is estimated to average 35 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Project Clearance Officer, 1600 Clifton Road, MS D-74, Atlanta, GA 30333, ATTN: PRA (0920-0026). Do not send the completed form to this address.

Information contained on this form which would permit identification of any individual has been collected with a guarantee that it will be held in strict confidence, will be used only for surveillance purposes, and will not be disclosed or released without the consent of the individual in accordance with Section 308(d) of the Public Health Service Act (42 U.S.C. 242m).

_State Case No. .

REPORT OF VERIFIED CASE OF TUBERCULOSIS

(Last)

17. Sputum Smear (select one)	Date Collected: Month	
Posit TB108	TB221	
18. Sputum Culture (select one)	Date Collected:	Date Result Reported:
□ Pacit	Month	Monti ear
TB109	TB223	□ TB225 □ □
L Nega		
	Reporting Laboratory Type (select one):	B227 Commercial aboratory Other
19. Smear/Pathology/Cytology of Tissue a	nd Other Body Fluids (select one)	
Pos	Date Collected:	Enter anatomic code Type of exam (select all that apply):
□ Neg TB110	TB228	TB111 □s TB230 ogy
	IBZZO	TB200
20. Culture of Tissue and Other Body Fluid	s (select one)	Enter
Positi	Date Collected:	anatomic code (see list): Date Result Reported:
□ _{Negat} TB113	Month Year	Month
	TB231	TB114 TB233
	Reporting Laboratory Type (select one):	TD224
	Labo	TB234
21. Nucleic Acid Amplification Test Result	(select one)	
	Collected:	Date Result Reported:
Negat TB235	TB236	TB240
☐ Indeterminate	18230	10240
Ente	r specimen type: TB238	Reporting Laboratory Type (select one):
OR		Public He Laborato TB242
II Not	Sputum, enter anatomic code (see list):	39
Initial Chest Radiograph and Other Chest	Imaging Study	
22A. Initial Chest Radiograph	al DAbnorr TB116 No	t Done Unknown
(select one)	* For ABNORMAL Initial Chest Radiograph:	Evidence of a cavity (select one): Yes 18243 nown
		Evidence of miliary TB (select one): Ye TB244 nown
22B. Initial Chest CT Scan or Other Chest Imaging	al DAbnorn TB245 DNo	t Done
Study (select one)	* For ABNORMAL Initial Chest Radiograph:	Evidence of a cavity (select one): Ye: TB246 nown
		Evidence of miliary TB (select one): Ye TB247 nown
23. Tuberculin (Mantoux) Skin Test		25. Primary Reason Evaluated for TB Disease (select one)
at Diagnosis (select one) Date Tu	uberculin Skin Test (TST) Placed: Millimeters	s (mm)
TB119 Mon		
L Neg uaro L omanomi	TB248 TB	
		Contact Investigation
24. Interferon Gamma Release Assay for Mycobacterium tuberculosis at Diag	Date Collected:	☐ Targeted Testing ☐ Health Care Worker
(select one)	TB251	Employment/Administrative Testing
Posi TR250		Immigration Medical Exam
Negative Donknown	Test type:	☐ Incidental Lab Result
☐ Indeterminate	Specify TB253	Unknown

26. HIV Status at Time of Diagnosis (select one)	
Negative	Not Offered Unknown
Positive TB122	Test Done, Results Unknown
If POSITIVE, enter:	City/County HIV/AIDS TB126
State HIV/AIDS Patient Number:	Patient Number:
	ent of Correctional Facility at Time of Diagnosis (select one)
	if YES, under custody of Immigration and Customs
BIZI POMOWII	deral Prison TB129 Other Correctional Facility Immigration and Customs Enforcement? (select one) TB29 Unknown No TB256
	I BZ30
29. Resident of Long-Term Care Facility at Time of If YES, (select one):	TB130 own
☐ Nursing Home ☐ Reside	Alcohol or Drug Treatment Facility
☐ Hospital-Based Facility ☐ Mental Health Re	esidential Facility Other Long-Term Care Facility
30. Primary Occupation Within the Past Year (select	ct one)
Health Care Worker	TB206 tetired Not Seeking Employment (e.g. student, homemaker, disabled person)
☐ Correctional Facility Employee ☐ Other Oct	dnemployed Unknown
31. Injecting Drug Use Within Past Year (select one)	32. Non-Injecting Drug Use Within Past Year (select one) (select one) (select one)
TB148 1known	
34. Additional TB Risk Factors (select all that apply)	
Contact of MDR-TB Patient (TB258
	Therapy End-Stage Renal Disease None
Missed Contact (2 years or less)	☐ Post-organ Transplantation ☐ Immunosuppression (not HIV/AIDS)
35. Immigration Status at First Entry to the U.S. (se	
☐ Not Applicable	ant Visa ☐ Tourist Visa ☐ Asylee or Parolee TB259 I Visa ☐ Family/Fiancé Visa ☐ Other Immigration Status
"U.Sborn" (or born abroad to a parent to a pare	The state of the s
Born in 1 of the U.S. Territories, U.S. Isla	nd Areas, or U.S. Outlying Areas
Month Day Year	37. Initial Drug Regimen (select one option for each drug) TB132 TB262
	Isoniazid Ethionamide Moxifloxacin
│	Aniampin Cycloserine Cycloserine
<u> </u>	Pyrazinamide TB 134 Kanamycin Salicylic Acid
	Other TP264
	Specify
	Rifapentine TB260 Ofloxacin TB145
Comments:	

Patient's Name _				REPORT OF VERIFIED CAS
	(Last)	(First)	(M.I.)	OF TUBERCULOSI
Street Address _				
		(Number, Stre	eet, City, State)	(ZIP CODE)

CDC

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) ATLANTA, GEORGIA 30333 FORM APPROVED OMB NO. 0920-0026 Exp. Date 05/31/2011

	eptibility Report			(Follow Up Report
/ear Counted	State	INV	173	
ar(TB100)	Case Number			
	City/County Case Number	INV	172	
				.
ıbmit this repo	rt for all culture- _l	positive cases		
3. Genotyping Accessio	n Number		TD266	
Isolate submitted for go	enotyping (select one):	□ No □ Yes □	ГВ266	
If YES, genotyping acc	ession number for episode:		ГВ267	
). Initial Drug Susceptib				· ·
			D456	
	testing done? (select one)		B156	
	l, do not complete the re			rpacol
If YES, enter date FIRS testing was done:	T isolate collected for which	h drug susceptibility	Enter specimen type: Sputum OR	FB268
Month Day	Year			enter anatomic code (see
TR	157		n not opatam,	enter anatomic code (see TB2
). Initial Drug Susceptib	ility Results (select one op	=-		
	TB158	Not Done Unknown	TR1	Susceptible Not Done Unknown
Isoniazid	TB159		Capreomycin TR4	70
Rifampin	TB160		TR2	
Pyrazinamide			Levotioxacin	
Ethambutol	TB161		TD2	
Streptomycin	TB162		TDO	
Rifabutin				
	TB169		TD4	
Rifapentine			Cycloserine TB1	65 🗆 🗆
Rifapentine Ethionamide	TB270		Para-Amino Salicylic Acid	65
Rifapentine	TB270 TB163		Para-Amino Salicylic Acid Other TB1	65
Rifapentine Ethionamide	TB270 TB163 TB168		Para-Amino Salicylic Acid Other Specify	65
Rifapentine Ethionamide Amikacin	TB270 TB163		Para-Amino Salicylic Acid Other TB1	65

Public reporting burden of this collection of information is estimated to average 35 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Project Clearance Officer, 1600 Clifton Road, MS D-74, Atlanta, GA 30333, ATTN: PRA (0920-0026). Do not send the completed form to this address.

Information contained on this form which would permit identification of any individual has been collected with a guarantee that it will be held in strict confidence, will be used only for surveillance purposes, and will not be disclosed or released without the consent of the individual in accordance with Section 308(d) of the Public Health Service Act (42 U.S.C. 242m).

Patient's Name _				REPORT OF VERIFIED CASE
	(Last)	(First)	(M.I.)	OF TUBERCULOSIS
Stroot Addroop				

Street Address	
	(Number, Street, City, State)



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)

ATLANTA, GEORGIA 30333 FORM APPROVED OMB NO. 0920-0026 Exp. Date 05/31/2011

Case Con	npletion	Report
----------	----------	--------

(Follow Up Report - 2)

Year Counted	State Case Number	INV173				
Year(TB100)	City/County Case Number	INV172				ر

Submit this report for all esses in which the nations was alive at diagnosis

41. Sputum Culture Conversion Documented (sel	ect one) \square No \square TB1	73 h	
If YES, enter date specimen collected for FIRST consistently negative sputum culture: Month Day Year TB175	If NO, enter reason for not doo	Patient Refused Other Specify Unknown	Patient Lost to Follow-Up
	(City) T	Specify	nty) TB284
43. Date Therapy Stopped	44. Reason Therapy Stopped	or Never Started (select one)	
Month Day Year TB176	Completed Therapy Lost TB1 Uncooperative or Refus Adverse Treatment Ever	ied Related to TB	1 1 BZ90 1
45. Reason Therapy Extended >12 months (selec	t all that apply)	_	
Rifampin Resis Adverse Drug F	Non-adherence	☐ Clinically Indicated – other reason ☐ Other Specify	292
46. Type of Outpatient Health Care Provider (sele	ct all that apply)	<u> </u>	
Local/State He Private Outpati	IHS, Tribal HD, or Tribal Corpora	ion Inpatient Care Only Other	Unknown
Comments:			

Public reporting burden of this collection of information is estimated to average 35 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Project Clearance Officer, 1600 Clifton Road, MS D-74, Atlanta, GA 30333, ATTN: PRA (0920-0026). Do not send the completed form to this address.

Information contained on this form which would permit identification of any individual has been collected with a guarantee that it will be held in strict confidence, will be used only for surveillance purposes, and will not be disclosed or released without the consent of the individual in accordance with Section 308(d) of the Public Health Service Act (42 U.S.C. 242m).

REPORT OF VERIFIED CASE
OF TUBERCULOSIS

Patient's Name			
	(Last)	(First)	



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) ATLANTA, GEORGIA 30333 FORM APPROVED OMB NO. 0920-0026 Exp. Date 05/31/2011

Case Completion Report - Continued (Follow Up Report - 2)

(M.I.)

State Case No. _

	(i diidii de ricedii 2
47. Directly Observed Therapy (DOT) (select one)	
No, Totally Self-Administered	
Yes, TB179 and Self-Administered	
Unknown	_
TR18	<mark>1 </mark>
Training of the sit and stay and a sit and appropriate the sit and sit	-
48. Final Drug Susceptibility Testing	
Was follow-up drug susceptibility testing done? (select one)	□Yes □Unknow TB182
If NO or UNKNOWN, do not complete the rest of Follow Up Report	:-2
If YES, enter date FINAL isolate collected for which drug susceptibility testing was done:	Enter specimen type: Sputum TB293
Month Day Year	If not Sputum, enter anatomic code (see TB29)
□ TB183	1220
49. Final Drug Susceptibility Results (select one option for each drug)	
Resistant Susceptible Not Done Unknown	Resistant Susceptible Not Done Unknown
Isoniazid TB184	Capreomycin TB192
Rifampin TB185	Ciprofloxacin
Pyrazinamide TB186	Levofloxacin TB296
Ethambutol TB187	Ofloxacin TB197
Streptomycin TB188	Moxifloxacin TB297
Rifabutin TB195	Other Quinolones TB298
Rifapentine TB295	Cycloserine TB191
Ethionamide TB189	Para-Amino Salicylic Acid TB193
Amikacin TB194	Other
Kanamycin TB190	SpecifyTB299
	Other TB300
	SpecifyTB301
Comments:	

Public reporting burden of this collection of information is estimated to average 35 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Project Clearance Officer, 1600 Clifton Road, MS D-74, Atlanta, GA 30333, ATTN: PRA (0920-0026). Do not send the completed form to this address.

Information contained on this form which would permit identification of any individual has been collected with a guarantee that it will be held in strict confidence, will be used only for surveillance purposes, and will not be disclosed or released without the consent of the individual in accordance with Section 308(d) of the Public Health Service Act (42 U.S.C. 242m).